New Frontiers in Uveitis Management: Five Drugs to Watch
The management of uveitis is rapidly evolving with the introduction of novel therapeutic molecules targeting key inflammatory pathways. This article highlights five promising drugs currently under clinical evaluation, offering hope for more effective and safer treatment options. While early results are encouraging, most of these agents are yet to complete phase 3 trials, and their long-term safety and efficacy remain to be established. Until then, clinicians must remain cautiously optimistic and await further evidence before these therapies can reshape uveitis care. 1. Brepocitinib Brepocitinib is an oral small-molecule inhibitor targeting Janus kinase 1 (JAK 1) and tyrosine kinase 2 (TYK2). Unlike many other JAK inhibitors that may block several JAK family kinases broadly (JAK1, JAK2, JAK3), brepocitinib selectively inhibits TYK2 and JAK1 while sparing JAK2 and JAK3 to a significant degree. This selectivity translates into targeted suppression of key pro-inflammatory cytokines—such as

